These videos, originally part of the RoB 2: Learning Live webinar series, explain how to assess risk of bias in cluster randomised trials and crossover trials. The additional signalling questions are also presented, along with worked examples.
This session was intended for people who are interested in using RoB 2 to assess risk of bias in their review, including cluster randomised or cross over trials. In addition to review author teams, CRG editors can learn about the risk of bias in these study designs so that they are able to assist authors with any queries they may have and also ensure information included in the review for this domain are relevant.
The webinar was delivered in December 2020 and below you will find the videos from the webinar, together with accompanying slides to download [PDF].
Part 1: Risk of Bias 2 for Crossover Trials
Part 2: Additional Considerations for Cluster Randomized Trials
Tianjing Li is an Associate Professor with tenure in the Department of Ophthalmology at University of Colorado Denver with a secondary appointment in the Department of Epidemiology at University of Colorado School of Public Health. Previously, she worked as an Associate Professor in the Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health where she was a core faculty member in the Center for Clinical Trials and Evidence Synthesis. The primary goal of Tianjing’s research is to develop, evaluate, and disseminate efficient methods for comparing healthcare interventions and to provide trust-worthy evidence for decision-making. She has worked with Cochrane in various capacities for 15 years, including serving as the Associate Director for Cochrane United States from 2012 to 2018, a Coordinating Editor for Cochrane Eyes and Vision, a co-convener for the Cochrane Comparing Multiple Interventions Methods Group, and an executive member of the Cochrane Methods Board. She is an Associate Scientific Editor for the 2nd edition of the Cochrane Handbook for Systematic Reviews of Interventions. Outside of Cochrane, Tianjing serves as an Editor-in-Chief for the journal Trials and the Review Editor for JAMA Ophthalmology.
Sandra Eldridge is Professor of Biostatistics and Director of the UKCRC Registered Pragmatic Clinical Trials Unit at Queen Mary. She is Associate Dean for Strategic Developments within the School for Medicine and Dentistry and lead for Equality, Diversity and Inclusion, an NIHR Senior Investigator, and Honorary Fellow of the Royal College of General Practitioners. Sandra has an international reputation as a trial statistician with particular interests in cluster randomised trials, pilot and feasibility studies and pragmatic trials. She currently leads the collaboration on pilot and feasibility studies that developed the CONSORT extension for pilot trials and has led the adaptation of the new Cochrane Risk of Bias tool to cluster randomised trials. In 2012, she published (together with Sally Kerry) the book “A practical guide to cluster randomised trials in health services research”. She collaborates widely, has over 200 peer-reviewed publications, and currently holds about £25 million of research grants as principal investigator or co-applicant..